Cytokines in CAR T Cell–Associated Neurotoxicity

Cytokines in CAR T Cell–Associated Neurotoxicity

Chimeric antigen receptor (CAR) T cells provide new therapeutic options for patients with relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and potentially fatal, complication. The spectrum of manifestations ranges from delirium and language dysfunction to seizures,...

Full description

Bibliographic Details
Main Authors:	Juliane Gust, Rafael Ponce, W. Conrad Liles, Gwenn A. Garden, Cameron J. Turtle
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-12-01
Series:	Frontiers in Immunology
Subjects:	CAR T cell ICANS Cytokines Neurotoxicity Blood Brain Barrier (BBB)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.577027/full

Similar Items

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
by: Castaneda-Puglianini O, et al.
Published: (2021-08-01)

Editorial: Novel insights into CAR T-cell associated neurotoxicity
by: Stella Bouziana
Published: (2023-11-01)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
by: Xinyi Xiao, et al.
Published: (2021-11-01)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
by: Robert C. Sterner, et al.
Published: (2022-08-01)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
by: Tim Lakomy, et al.
Published: (2023-02-01)

Novel pathophysiological insights into CAR-T cell associated neurotoxicity
by: Vassilis Genoud, et al.
Published: (2023-03-01)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
by: Semira Sheikh, et al.
Published: (2022-02-01)

CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
by: Lidia Gatto, et al.
Published: (2023-06-01)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01)

A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
by: Omar H. Butt, et al.
Published: (2023-02-01)

The Mechanisms of Altered Blood–Brain Barrier Permeability in CD19 CAR T–Cell Recipients
by: Soniya N. Pinto, et al.
Published: (2024-01-01)

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
by: Roser Velasco, et al.
Published: (2023-04-01)

Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
by: Beatriz Martín-Antonio
Published: (2021-03-01)

The Integrity of the Blood–Brain Barrier as a Critical Factor for Regulating Glutamate Levels in Traumatic Brain Injury
by: Matthew Boyko, et al.
Published: (2023-03-01)

Immunotherapy Associated Neurotoxicity in Pediatric Oncology
by: Haneen Shalabi, et al.
Published: (2022-02-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Misadventures in Toxicology: Concentration Matters for Testosterone-Induced Neurotoxicity
by: Cyril Willson
Published: (2023-03-01)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
by: Felix Korell, et al.
Published: (2022-04-01)

The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
by: Giada Del Baldo, et al.
Published: (2023-03-01)

Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
by: Avis Harden, et al.
Published: (2020-08-01)

Building safety into CAR-T therapy
by: Daniel T. Peters, et al.
Published: (2023-12-01)

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
by: Yanping Li, et al.
Published: (2022-10-01)

Chronic Low Dose Morphine Does Not Alter Two In Vitro BBB Models
by: Jamie Marino, et al.
Published: (2022-07-01)

Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke
by: Umberto Pensato, et al.
Published: (2020-10-01)

Difenoconazole disrupts the blood-brain barrier and results in neurotoxicity in carp by inhibiting the Nrf2 pathway mediated ROS accumulation
by: Feixue Liu, et al.
Published: (2022-10-01)

Glutamate Neurotoxicity and Destruction of the Blood–Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies
by: Benjamin F. Gruenbaum, et al.
Published: (2022-08-01)

Akinetic mutism in COVID-19-related encephalopathy: A cytokine-mediated maladaptive sickness behavioral response?
by: Umberto Pensato, et al.
Published: (2021-08-01)

Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation
by: Susanne H. C. Baumeister, et al.
Published: (2022-03-01)

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
by: Jessica I. Griffith, et al.
Published: (2020-12-01)

Peptide Shuttles for Blood–Brain Barrier Drug Delivery
by: Macarena Sánchez-Navarro, et al.
Published: (2022-09-01)

Secretory co-factors in next-generation cellular therapies for cancer
by: Atsushi Okuma, et al.
Published: (2022-08-01)

A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells
by: Nicole L. Stone, et al.
Published: (2019-06-01)

Filter exchange imaging with crusher gradient modelling detects increased blood–brain barrier water permeability in response to mild lung infection
by: Yolanda Ohene, et al.
Published: (2023-04-01)

Modulating the Blood–Brain Barrier: A Comprehensive Review
by: Rory Whelan, et al.
Published: (2021-11-01)

Bisphenol A Inhibits the Transporter Function of the Blood-Brain Barrier by Directly Interacting with the ABC Transporter Breast Cancer Resistance Protein (BCRP)
by: Elin Engdahl, et al.
Published: (2021-05-01)

Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion
by: Rongliang Wang, et al.
Published: (2016-01-01)

Co-Culture Models: Key Players in In Vitro Neurotoxicity, Neurodegeneration and BBB Modeling Studies
by: Ana Rita Monteiro, et al.
Published: (2024-03-01)

Glioblastoma Multiforme—A Look at the Past and a Glance at the Future
by: Jasmine L. King, et al.
Published: (2021-07-01)

Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET
by: Shengkai Xia, et al.
Published: (2024-04-01)

The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier
by: William M. Pardridge
Published: (2020-05-01)